New Mechanisms in Glucose Control presents a clear overview
of the new drugs and treatment therapies that have been developed
in recent years to help improve glycaemic management for
the diabetic patient, namely the incretin mimetics (GLP-1 agonists)
and DPP-4 inhibitors. It also considers other drug classes
currently in development and undergoing clinical trials including
the SGLT2 inhibitors and other pipeline products. In addition to
pharma cotherapeutic agents, the role of bariatric as a management
tool for diabetes is covered as well as consideration of the
organisation of diabetes care with a community focus.
This indispensable pocketbook details the newer treatments and
offers a comparison with more traditional agents including
sulphonyureas, glitazones and insulin. The pros and cons of
traditional therapies are discussed as well as the epidemiology and
pathogenesis of type 2 diabetes, helping to give the reader a
better understanding of the disease area and its
management.
New Mechanisms in Glucose Control is essential reading
for health professionals working in primary or secondary care and
involved in treating diabetic patients.

Innehållsförteckning

Om författaren